{
    "Trade/Device Name(s)": [
        "Dexcom G7 Continuous Glucose Monitoring (CGM) System"
    ],
    "Submitter Information": "Dexcom, Inc.",
    "510(k) Number": "K213919",
    "Predicate Device Reference 510(k) Number(s)": [
        "K201328"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "QBJ"
    ],
    "Summary Letter Date": "September 14, 2022",
    "Summary Letter Received Date": "September 15, 2022",
    "Submission Date": "November 29, 2022",
    "Regulation Number(s)": [
        "21 CFR 862.1355"
    ],
    "Regulation Name(s)": [
        "Integrated continuous glucose monitoring system"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Glucose"
    ],
    "Specimen Type(s)": [
        "Interstitial fluid"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Dexcom G7 CGM System (Glucose Sensing Subsystem, Mobile Application Subsystem, Receiver Subsystem)",
        "Mobile app",
        "Receiver"
    ],
    "Method(s)/Technology(ies)": [
        "Amperometric measurement",
        "Glucose oxidase chemical reaction",
        "Bluetooth wireless data transmission",
        "Factory calibration",
        "Optional manual calibration"
    ],
    "Methodologies": [],
    "Submission Type(s)": [
        "System",
        "Sensor",
        "Receiver",
        "Mobile Application",
        "Accessory"
    ],
    "Document Summary": "FDA 510(k) summary for Dexcom G7 Continuous Glucose Monitoring System for real-time glucose measurement and diabetes management in persons 2 years and older.",
    "Indications for Use Summary": "Indicated for management of diabetes in persons 2 years and older, replaces fingerstick BG testing, aids detection of hyperglycemia and hypoglycemia, and communicates with digitally connected devices including automated insulin dosing systems.",
    "fda_folder": "Clinical Chemistry"
}